haloperidol has been researched along with Breast Neoplasms in 16 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 9.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 7.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "The sigma receptor ligand reduced haloperidol (50 and 100 microM), potently inhibited cell proliferation, and induced apoptosis in WIDr colon and MCF-7 adenocarcinoma cell lines." | 7.69 | The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. ( Brent, PJ; Dosen, PJ; Little, G; Pang, G; Van Helden, DF, 1996) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 5.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 3.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "The sigma receptor ligand reduced haloperidol (50 and 100 microM), potently inhibited cell proliferation, and induced apoptosis in WIDr colon and MCF-7 adenocarcinoma cell lines." | 3.69 | The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. ( Brent, PJ; Dosen, PJ; Little, G; Pang, G; Van Helden, DF, 1996) |
| "MCF-7 breast cancer cells were trypsinized and plated in 24-well plates at initial concentrations of 10,000 cells per well in 5% FBS in DME." | 1.31 | The effect of AH 26 and AH Plus on MCF-7 breast cancer cell proliferation in vitro. ( Fernández, MF; Olea, N; Pulgar, R; Segura-Egea, JJ; Serna, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| John, CS | 2 |
| Vilner, BJ | 2 |
| Bowen, WD | 3 |
| Piergentili, A | 1 |
| Amantini, C | 1 |
| Del Bello, F | 1 |
| Giannella, M | 1 |
| Mattioli, L | 1 |
| Palmery, M | 1 |
| Perfumi, M | 1 |
| Pigini, M | 1 |
| Santoni, G | 1 |
| Tucci, P | 1 |
| Zotti, M | 1 |
| Quaglia, W | 1 |
| Germain, AR | 1 |
| Carmody, LC | 1 |
| Nag, PP | 1 |
| Morgan, B | 1 |
| Verplank, L | 1 |
| Fernandez, C | 1 |
| Donckele, E | 1 |
| Feng, Y | 1 |
| Perez, JR | 1 |
| Dandapani, S | 1 |
| Palmer, M | 1 |
| Lander, ES | 1 |
| Gupta, PB | 1 |
| Schreiber, SL | 1 |
| Munoz, B | 1 |
| Spruce, BA | 1 |
| Campbell, LA | 1 |
| McTavish, N | 1 |
| Cooper, MA | 1 |
| Appleyard, MV | 1 |
| O'Neill, M | 1 |
| Howie, J | 1 |
| Samson, J | 1 |
| Watt, S | 1 |
| Murray, K | 1 |
| McLean, D | 1 |
| Leslie, NR | 1 |
| Safrany, ST | 1 |
| Ferguson, MJ | 1 |
| Peters, JA | 1 |
| Prescott, AR | 1 |
| Box, G | 1 |
| Hayes, A | 1 |
| Nutley, B | 1 |
| Raynaud, F | 1 |
| Downes, CP | 1 |
| Lambert, JJ | 1 |
| Thompson, AM | 1 |
| Eccles, S | 1 |
| Mukherjee, A | 1 |
| Prasad, TK | 1 |
| Rao, NM | 1 |
| Banerjee, R | 1 |
| Cole, RM | 1 |
| Robinson, F | 1 |
| Harvey, L | 1 |
| Trethowan, K | 1 |
| Murdoch, V | 1 |
| Johnson, DE | 1 |
| Ochieng, J | 1 |
| Evans, SL | 1 |
| Brent, PJ | 1 |
| Pang, G | 1 |
| Little, G | 1 |
| Dosen, PJ | 1 |
| Van Helden, DF | 1 |
| Garrido, SM | 1 |
| Chauncey, TR | 1 |
| Climent, MA | 1 |
| Palau, J | 1 |
| Ruiz, A | 1 |
| Soriano, V | 1 |
| Aznar, E | 1 |
| Olmos, T | 1 |
| Guillem, V | 1 |
| Strobl, JS | 1 |
| Melkoumian, Z | 1 |
| Peterson, VA | 1 |
| Hylton, H | 1 |
| Crawford, KW | 1 |
| Silvey, L | 1 |
| Carpenter, JT | 1 |
| Wheeler, RH | 1 |
| Lee, J | 1 |
| Conolley, C | 1 |
| Pulgar, R | 1 |
| Segura-Egea, JJ | 1 |
| Fernández, MF | 1 |
| Serna, A | 1 |
| Olea, N | 1 |
| Zweyer, M | 1 |
| Troian, B | 1 |
| Spreafico, V | 1 |
| Prato, S | 1 |
1 trial available for haloperidol and Breast Neoplasms
| Article | Year |
|---|---|
A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
15 other studies available for haloperidol and Breast Neoplasms
| Article | Year |
|---|---|
Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells.
Topics: Animals; Benzamides; Binding Sites; Breast Neoplasms; Guinea Pigs; Humans; Iodine Radioisotopes; Pip | 1994 |
Novel highly potent and selective sigma 1 receptor antagonists related to spipethiane.
Topics: Analgesics; Animals; Antineoplastic Agents; Apoptosis; Binding, Competitive; Breast Neoplasms; Cell | 2010 |
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Topics: Amides; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Neopla | 2013 |
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Calcium Signaling; Carbazoles; Caspases | 2004 |
Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cells.
Topics: Antipsychotic Agents; Breast Neoplasms; Female; Gene Transfer Techniques; Haloperidol; HeLa Cells; H | 2005 |
Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Haloperidol; Humans | 1994 |
The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Breast Neoplasms; Cell Division; Dopamin | 1995 |
Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines.
Topics: Adenocarcinoma; Animals; Binding, Competitive; Breast Neoplasms; Carcinoma, Ductal, Breast; Glioblas | 1995 |
The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Bisbenzimidazole; Breast Neoplasms; Calcium; Cell Line; Chromatin; Coloni | 1996 |
Neuroleptic malignant syndrome following autologous peripheral blood stem cell transplantation.
Topics: Antipsychotic Agents; Breast Neoplasms; Droperidol; Female; Haloperidol; Hematopoietic Stem Cell Tra | 1998 |
The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; | 1998 |
The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide.
Topics: Antipsychotic Agents; Apoptosis; Breast Neoplasms; Cell Division; Female; Flow Cytometry; Gamma Rays | 1998 |
Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Breast Neoplasms; Caspases; Cyclophosphamid | 2002 |
The effect of AH 26 and AH Plus on MCF-7 breast cancer cell proliferation in vitro.
Topics: Benzhydryl Compounds; Bismuth; Breast Neoplasms; Cell Division; Drug Combinations; Epoxy Resins; Est | 2002 |
SNOM on cell thin sections: observation of Jurkat and MDAMB453 cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Epoxy Resins; Female; Humans; Jurkat Cells; Mammary Glands, Huma | 2008 |